🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise around the world, with estimates suggesting over 82 million instances per year. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Data and Worldwide Availability

As per results detailed in a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The trial included nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Doctors directly involved have shared optimism. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is considered crucial to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.